Thalidomide and dexamethasone for resistant multiple myeloma

Between November 1998 and April 2000, the combination of thalidomide and dexamethasone was evaluated in 47 consecutive patients with multiple myeloma that was resistant to prior high‐dose dexamethasone‐based therapies. Remission was observed in 22 patients (47%), including six patients with complete...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2003-06, Vol.121 (5), p.768-777
Main Authors: Anagnostopoulos, Athanasios, Weber, Donna, Rankin, Kim, Delasalle, Kay, Alexanian, Raymond
Format: Article
Language:English
Subjects:
Adult
Aged
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
Chemotherapy
dexamethasone
Dexamethasone - administration & dosage
Dexamethasone - adverse effects
Drug Resistance, Neoplasm
Hematology
Humans
Immunodeficiencies. Immunoglobulinopathies
Immunoglobulinopathies
Immunopathology
Medical sciences
Middle Aged
multiple myeloma
Multiple Myeloma - drug therapy
Pharmacology. Drug treatments
Prognosis
Remission Induction
Survival Analysis
thalidomide
Thalidomide - administration & dosage
Thalidomide - adverse effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Between November 1998 and April 2000, the combination of thalidomide and dexamethasone was evaluated in 47 consecutive patients with multiple myeloma that was resistant to prior high‐dose dexamethasone‐based therapies. Remission was observed in 22 patients (47%), including six patients with complete remission. Side‐effects were frequent, mild and usually reversible, but deep vein thrombosis occurred in 8% of patients. Survival and remission times were longer among patients treated for previous resistant disease rather than for resistant relapse. This experience supports the use of thalidomide–dexamethasone in myeloma patients with resistant disease and justifies further trials in newly diagnosed patients.
ISSN:0007-1048
1365-2141
DOI:10.1046/j.1365-2141.2003.04345.x